Bli medlem
Bli medlem

Du är här


Ropack, Inc.: Ropack Pharma Solutions Appoints Francois Chouinard, Ph.D., Director of Business Development for R&D and Formulation

MONTREAL, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Ropack Pharma Solutions (RPS),
provider of high-quality drug development, manufacturing and packaging of
solid oral dosage, has hired Francois Chouinard, Ph.D., as Director of
Business Development for R&D and Formulation. Chouinard will report to Paul
Dupont, VP, Marketing and Business Development.

A photo accompanying this announcement is available

Chouinard, who holds a doctorate in Pharmaceutical Sciences, will focus on
business development for the drug development facilities in Long Island, New
York, purchased by RPS and most recently operated by Forest Labs. "Francois
brings a deep understanding of the drug development process," said Dupont.
"His many years of success and experience working in the CDMO/CMO
environment, along with his superior customer engagement skills and
scientific background, are unique and valuable assets which will advance and
support our mission to provide a superior customer engagement experience."

An internationally experienced Pharma R&D leader, he brings more than 20 years
of experience in the generic, contract development and biotech industries,
developing more than 30 solid dose products for the Canadian and European
markets. Prior to joining RPS, he was Executive Director of Product
Development at Halo Pharmaceutical's Montreal location where he was actively
involved in the development of new business opportunities as well as the
management of all product development.

"With Ropack Pharma Solutions now providing a complete range of contract
development services, my product development experience in brand and generic
Pharma will help RPS support the best development strategy for our customers
and establish a high level of confidence in our ability to meet their
timelines and product quality attributes," noted Chouinard.

About Ropack Pharma Solutions

Ropack Pharma Solutions (RPS) supports solid oral dosage projects from
early-stage formulation through clinical manufacturing, packaging,
distribution and commercial manufacturing and packaging. Facilities in
Montreal, Canada, and Long Island, New York, are cGMP-compliant,
site-licensed by the FDA and Health Canada-certified.

Paul Dupont
Ropack Pharma Solutions
10801 Mirabeau, Montr?al, Qu?bec H1J 1T7, CANADA


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ropack, Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.